PMID- 28000168
OWN - NLM
STAT- MEDLINE
DCOM- 20170814
LR  - 20181202
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 34
IP  - 2
DP  - 2017 Feb
TI  - Caregiver Preference and Treatment Compliance in Patients with Mild-to-Moderate 
      Alzheimer's Disease in South Korea: RECAP Study Results.
PG  - 481-494
LID - 10.1007/s12325-016-0465-8 [doi]
AB  - INTRODUCTION: The aim of this study was to assess caregiver preference and 
      treatment compliance with oral and transdermal medications in a "real-world" 
      setting in patients with mild-to-moderate Alzheimer's disease (AD) in South 
      Korea. METHODS: Real-world evaluation of compliance and preference in Alzheimer's 
      disease treatment (RECAP) was a 24-week, multicenter, prospective, 
      non-interventional study in patients with AD treated with oral or transdermal 
      therapy. Here, we report data from patients living in South Korea. Eligible 
      patients were grouped into one of two treatment cohorts: oral (donepezil, 
      galantamine, rivastigmine, or memantine) or transdermal (rivastigmine patch). 
      Caregiver preference, patient compliance, and physician preference were assessed 
      at week 24 (end of the study). Safety was assessed by reported adverse events 
      (AEs). RESULTS: A total of 398 patients were enrolled (oral 51.8%; transdermal 
      48.2%) and 79.4% completed the study. Caregivers of patients that were exposed to 
      either the oral or transdermal monotherapy showed a preference for the treatment 
      to which the patients were exposed (both p < 0.0001). However, caregivers of 
      patients that were exposed to both forms of treatments reported a higher 
      preference for transdermal monotherapy (65.9%; p < 0.0041). Patients in both 
      treatment cohorts showed good compliance, with an overall mean (SD) score of 8.84 
      (1.514) (a median of 9). Of the 15 participating physicians, eight indicated 
      their preference for transdermal therapy and seven preferred oral therapy at week 
      24. A total of 133 (33.4%) patients reported at least one AE during the study 
      period (oral: 60 patients; transdermal: 73 patients). CONCLUSION: The study 
      showed higher caregiver preference for transdermal monotherapy over oral 
      monotherapy when patients with AD were exposed to both forms of treatment and 
      good patient compliance for both oral and transdermal treatments.
FAU - Lee, Kang Joon
AU  - Lee KJ
AD  - Department of Psychiatry, College of Medicine, Inje University Ilsan Paik 
      Hospital, Goyang-Si, South Korea.
FAU - Cho, Seong-Jin
AU  - Cho SJ
AD  - Department of Psychiatry, Gachon University of Gil Hospital, Incheon, South 
      Korea.
FAU - Kim, Byeong Chae
AU  - Kim BC
AD  - Department of Neurology, Chonnam National University Medical School, Gwangju, 
      South Korea.
FAU - Park, Minseok
AU  - Park M
AD  - Novartis Korea Ltd., Seoul, South Korea.
FAU - Lee, Jae-Hong
AU  - Lee JH
AUID- ORCID: 0000-0001-7368-4560
AD  - Department of Neurology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, South Korea. jhlee@amc.seoul.kr.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20161220
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Neuroprotective Agents)
RN  - PKI06M3IW0 (Rivastigmine)
MH  - Aged
MH  - *Alzheimer Disease/diagnosis/drug therapy/epidemiology
MH  - Caregivers/*psychology
MH  - Consumer Behavior/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuroprotective Agents/therapeutic use
MH  - Patient Compliance/*statistics & numerical data
MH  - Prospective Studies
MH  - Psychiatric Status Rating Scales
MH  - Republic of Korea/epidemiology
MH  - Rivastigmine/*therapeutic use
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Caregiver preference
OT  - Cholinesterase inhibitors
OT  - Rivastigmine
OT  - Transdermal patch
EDAT- 2016/12/22 06:00
MHDA- 2017/08/15 06:00
CRDT- 2016/12/22 06:00
PHST- 2016/08/08 00:00 [received]
PHST- 2016/12/22 06:00 [pubmed]
PHST- 2017/08/15 06:00 [medline]
PHST- 2016/12/22 06:00 [entrez]
AID - 10.1007/s12325-016-0465-8 [pii]
AID - 10.1007/s12325-016-0465-8 [doi]
PST - ppublish
SO  - Adv Ther. 2017 Feb;34(2):481-494. doi: 10.1007/s12325-016-0465-8. Epub 2016 Dec 
      20.